<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="801">
  <stage>Registered</stage>
  <submitdate>10/09/2005</submitdate>
  <approvaldate>10/09/2005</approvaldate>
  <nctid>NCT00182143</nctid>
  <trial_identification>
    <studytitle>PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)</studytitle>
    <scientifictitle>PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ISRCTN54618366</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Critical Illness</healthcondition>
    <healthcondition>Deep Venous Thrombosis</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - LMWH (Fragmin, dalteparin)
Treatment: drugs - Unfractionated Heparin

Active Comparator: LMWH (Fragmin, dalteparin) - Placebo dose (normal saline) = AM dose LMWH (Fragmin, dalteparin) 5000IU daily = PM dose

Active Comparator: 2 - Unfractionated Heparin 5000IU BID


Treatment: drugs: LMWH (Fragmin, dalteparin)
Placebo AM dose (normal saline) and LMWH (Fragmin, dalteparin) 5000IU PM dose

Treatment: drugs: Unfractionated Heparin
5000 IU BID

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To evaluate the effect of LMWH (Fragmin, dalteparin) versus UFH on the primary outcome of proximal leg DVT diagnosed by compression ultrasound</outcome>
      <timepoint>While in ICU to a maximum of 90 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the effect of LMWH (Fragmin, dalteparin) versus UFH on the secondary outcomes of PE, bleeding, HIT, and objectively confirmed venous thrombosis at any site</outcome>
      <timepoint>While in ICU to a maximum of 90 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Patient is &gt;/= 18 years of age

          2. Actual body weight is &gt;/= 45 kg

          3. Admission to ICU expected to be &gt;/= 72 hours in duration</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Neurosurgery within last 3 months

          2. Ischemic stroke within last 3 months

          3. Intracranial hemorrhage within last 3 months

          4. Systolic Blood Pressure &gt;/= 180mm Hg, Diastolic Blood Pressure &gt;/= 110mm Hg for &gt;/= 12
             hours requiring vasoactive drug infusion

          5. Major hemorrhage within last week unless definitively treated

          6. Coagulopathy as defined by INR &gt;/= 2 times upper limit of normal [ULN], or PTT &gt;/= 2
             times ULN, at time of screening

          7. Thrombocytopenia defined as platelet count &lt;/= 75 x 109/L, at time of screening

          8. Other heparin contraindications (e.g., HIT, pregnancy, lactating)

          9. Contraindication to blood products (e.g., Jehovah's Witness)

         10. Unable to perform lower limb ultrasound (e.g., bilateral above the knee amputation, or
             severe distal extremity burns)

         11. Limitation of life support, Life expectancy &lt;/= 14 days, or palliative care

         12. Contamination (e.g., &gt;/= 3 doses of LMWH during this ICU admission)

         13. Lack of informed consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>3659</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC</recruitmentstate>
    <hospital>Blacktown Hospital - Blacktown</hospital>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>Nepean Hospital - Penrith</hospital>
    <hospital>Wollongong Hospital - Wollongong</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Lyell McEwin Hospital - Elizabeth Vale</hospital>
    <hospital>Flinders Hospital - Bedford Park</hospital>
    <hospital>Bendigo Health Care - Bendigo</hospital>
    <hospital>Box Hill Hospital - Box Hill</hospital>
    <hospital>Monash Medical Center - Clayton</hospital>
    <hospital>Dandenong Hospital - Dandenong</hospital>
    <hospital>Frankston Hospital - Frankston</hospital>
    <hospital>The Geelong Hospital - Geelong</hospital>
    <hospital>Austin Hill Hospital - Heidelburg</hospital>
    <hospital>Royal Melbourne Hospital - Melbourne</hospital>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <postcode>2148 - Blacktown</postcode>
    <postcode> - Camperdown</postcode>
    <postcode> - Penrith</postcode>
    <postcode> - Wollongong</postcode>
    <postcode> - Adelaide</postcode>
    <postcode>5112 - Elizabeth Vale</postcode>
    <postcode> - Bedford Park</postcode>
    <postcode> - Bendigo</postcode>
    <postcode> - Box Hill</postcode>
    <postcode> - Clayton</postcode>
    <postcode>3168 - Dandenong</postcode>
    <postcode> - Frankston</postcode>
    <postcode>3220 - Geelong</postcode>
    <postcode> - Heidelburg</postcode>
    <postcode>3101 - Melbourne</postcode>
    <postcode>3181 - Melbourne</postcode>
    <postcode>NSW 2065 - St Leonards</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rs Cep</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>RS</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rio de Janeiro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Saudi Arabia</country>
      <state>Riyahd</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Saudi Arabia</country>
      <state>Jeddah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Saudi Arabia</country>
      <state>Riyadh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>England</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>McMaster University</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Canadian Institutes of Health Research (CIHR)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Canadian Critical Care Trials Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Australian and New Zealand Intensive Care Society Clinical Trials Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH)
      (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal
      leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary
      outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and
      objectively confirmed venous thrombosis at any site.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00182143</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Deborah J Cook, MD</name>
      <address>McMaster University</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>